Eva De Smedt
Brussels, BRU, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin-degrading enzyme, a new molecular vulnerability in multiple myeloma.
Journal: British journal of pharmacology
Published: October 14, 2024
Development and validation of a high-throughput screening pipeline of compound libraries to target EMT.
Journal: Cell death and differentiation
Published: May 27, 2024
Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma.
Journal: Clinical epigenetics
Published: November 12, 2020
The EMT Transcription Factor ZEB2 Promotes Proliferation of Primary and Metastatic Melanoma While Suppressing an Invasive, Mesenchymal-Like Phenotype.
Journal: Cancer research
Published: August 01, 2019
The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response.
Journal: Frontiers in oncology
Published: October 01, 2018
The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma.
Journal: British journal of cancer
Published: September 07, 2018
ZEB2 stably represses RAB25 expression through epigenetic regulation by SIRT1 and DNMTs during epithelial-to-mesenchymal transition.
Journal: Epigenetics & chromatin
Published: July 12, 2018
Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
Journal: Cancer research
Published: May 31, 2017
Epithelial-to-Mesenchymal Transition: Epigenetic Reprogramming Driving Cellular Plasticity.
Journal: Trends in genetics : TIG
Published: April 23, 2017
EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research.
Journal: Nature methods
Published: March 01, 2017
Last Updated: 09/26/2026